Why Are Moderna and Pfizer No Longer Authorized?

The original Moderna and Pfizer-BioNTech COVID-19 vaccines lost their authorizations because the virus they were designed to fight no longer exists in any meaningful sense. Both vaccines targeted the ancestral Wuhan strain of SARS-CoV-2, and as the virus mutated through Delta, Omicron, and a cascade of Omicron sublineages, the match between the vaccines and circulating strains deteriorated so sharply that regulators pulled the old formulations and replaced them with updated versions. The story is less about something going wrong with those vaccines and more about a virus that refused to hold still.

What the Original Vaccines Were Built to Do

Both the Pfizer-BioNTech vaccine (BNT162b2, later branded Comirnaty) and the Moderna vaccine (mRNA-1273, later branded Spikevax) encoded the spike protein of the original SARS-CoV-2 virus first identified in late 2019. They taught your immune system to recognize that specific spike shape so it could intercept the virus before it caused serious illness. In clinical trials conducted during 2020, both performed remarkably well against the strain circulating at the time, and they were granted Emergency Use Authorization (EUA) by the FDA in December 2020 and January 2021, respectively. Pfizer’s vaccine later received full FDA approval in August 2021, and Moderna’s followed in January 2022.

The EUA process allowed these vaccines to reach the public faster than the traditional approval pathway, which was critical during a pandemic. But the speed of authorization also created a public perception gap: some people viewed EUA products as less thoroughly vetted than fully approved ones, which contributed to hesitancy even as clinical evidence accumulated in their favor.¹ That distinction between EUA and full approval would become relevant again when regulators later had to revoke authorizations for outdated formulations while simultaneously authorizing new ones.

How Omicron Broke the Original Match

The original vaccines were designed around a spike protein that, by late 2021, was already a relic. When Omicron (BA.1) arrived, it carried more than 30 mutations in its spike protein compared to the ancestral strain. The practical result was stark: four weeks after the second dose of the Pfizer vaccine, the ability of antibodies to neutralize Omicron measured about 14-fold lower than their ability to neutralize the original strain.² Moderna’s booster sera showed a similar pattern, with Omicron sublineages escaping neutralization by roughly 5 to 12 times compared to the original target.³

This was not a failure of the vaccines so much as a feature of how coronaviruses work. SARS-CoV-2 kept mutating in the spike region that the vaccines trained your immune system to recognize. Each new Omicron sublineage (BA.2, BA.5, XBB, JN.1) drifted further from the original blueprint, and by 2023 the ancestral strain was effectively extinct in circulation. Continuing to authorize a vaccine targeting a virus that no longer existed made about as much sense as shipping last year’s flu shot.

Antibodies Were Already Fading Before Omicron Arrived

Even against the original strain, antibody levels from the primary two-dose series dropped quickly. One analysis estimated that people lost more than 99% of their peak antibody levels by about eight months after the second dose, with the half-life of antibodies after the primary series sitting around 63 days.⁴⁵ That sounds alarming, but it is worth understanding what it actually means. Antibodies are the first line of defense, but they are not the only line. Memory B cells and T cells persist much longer and can ramp up a response when they encounter the virus again.

A longer-term study tracking vaccinated individuals for over a year found that after an initial steep drop of about five-fold, antibody levels stabilized rather than continuing to fall toward zero.⁶ So the immune system did hold some memory. But the combination of waning antibodies and a dramatically different virus meant that the original formulation was offering diminishing returns on both fronts simultaneously. Regulators needed to address the mismatch, not just the decline.

Updated Formulations Proved the Point

The case for pulling the original vaccines was strengthened by evidence that updated formulations performed meaningfully better. In the COVAIL trial, boosting with a variant-containing vaccine produced higher neutralizing antibody levels against circulating strains than boosting with the original prototype vaccine. Critically, updated vaccines targeting Omicron BA.1 or Beta did not sacrifice immunity against the ancestral strain, meaning people did not lose their old protection by gaining new protection.⁷

Moderna’s bivalent vaccine (combining the original and BA.4/BA.5 spikes) showed strong results in its phase 2/3 trial. Against the BA.4/BA.5 sublineages that were dominant at the time, the bivalent version produced neutralizing antibody levels more than six times higher than the original monovalent booster.⁸ A separate study comparing bivalent and monovalent boosters found that bivalent vaccines not only generated higher antibody levels against Omicron subvariants but also improved the ability of existing memory B cells to recognize newer subvariants, something the original monovalent boosters could not do as well.⁹

With this evidence in hand, the FDA moved to a model similar to the annual flu vaccine update. The original formulations were deauthorized, first the monovalent versions in late 2022 when bivalent boosters replaced them, and then the bivalent versions themselves in 2023 when monovalent XBB.1.5-targeting vaccines took over. Each cycle retired the previous formulation because it no longer matched what was circulating.

The Immune Imprinting Problem

One complication that made the transition more scientifically interesting is a phenomenon called immune imprinting, sometimes referred to by the older and more dramatic name “original antigenic sin.” When your immune system first encounters a pathogen or vaccine, it forms a strong memory of that specific version. When it later encounters something similar but not identical, it tends to dust off the old playbook rather than building a new one from scratch. The result is that antibodies produced after an Omicron infection in someone previously vaccinated with the original vaccine tend to skew toward the ancestral strain’s features rather than the new epitopes unique to Omicron.¹⁰

This is not just an academic curiosity. If the virus continues to evolve away from the ancestral strain, and the immune system keeps recycling its original template, there is a risk that immune responses become progressively less effective against new variants. Researchers have specifically noted that the ancestral vaccine or infection can weaken the neutralizing antibody response against Omicron subvariants like BA.2 and XBB.¹¹ This has pushed vaccine designers to explore next-generation approaches, including vaccines built around conserved regions of the spike protein that are less likely to mutate, with the goal of overcoming imprinting from prior vaccination.¹²

Continuing to boost with the original formulation would have made the imprinting problem worse. Removing it from the market was not just about chasing the latest variant; it was also about not reinforcing an outdated immune template that could hamper future responses.

Myocarditis and the Safety Picture

Safety monitoring also played a role in how the vaccines were managed, though it was not the primary reason the original formulations lost authorization. After hundreds of millions of doses were administered globally, a rare but real signal emerged: mRNA vaccines, particularly Moderna’s, were associated with an increased risk of myocarditis and pericarditis in younger people, especially young men. An Italian surveillance study found the highest risk in males aged 12 to 39 after the second dose of Moderna’s vaccine, with roughly 9 extra cases per 100,000 vaccinated in that group.¹³ A U.S. analysis found the highest risk in males aged 12 to 17, at roughly 6 cases per 100,000 second doses.¹⁴

Most of these myocarditis cases were mild, self-limiting, and far less dangerous than the cardiac complications that could result from a COVID-19 infection itself. But the signal led to dose adjustments and age-specific recommendations rather than outright withdrawal for safety reasons. The fact that the vaccines were later deauthorized was fundamentally about efficacy against the circulating virus, not about safety concerns prompting removal. The safety monitoring infrastructure that caught the myocarditis signal, including systems like V-safe and VAERS, continued to track updated formulations in the same way.¹⁵¹⁶

What Happened to the Johnson and Johnson Vaccine

People sometimes conflate the deauthorization of the original Moderna and Pfizer formulations with the separate story of the Johnson and Johnson (Janssen) vaccine. The Janssen vaccine, which used a viral vector rather than mRNA, was associated with a different and more serious safety concern: thrombosis with thrombocytopenia syndrome (TTS), a rare blood clotting disorder. The CDC and FDA paused its use in April 2021 after six initial U.S. cases of cerebral venous sinus thrombosis with low platelet counts were reported among recipients.¹⁷ The Janssen vaccine was eventually pulled from the U.S. market in 2023 primarily because of this safety issue, combined with the availability of safer mRNA alternatives. That is a fundamentally different trajectory from the mRNA vaccines, which were deauthorized because they became outdated, not because they were unsafe.

Children and the Rolling Authorization Timeline

The authorization timeline for children added another layer of complexity. Pediatric formulations of the mRNA vaccines were developed and authorized after the adult versions, following age-stepped rollouts from adolescents down to children as young as six months old.¹⁸ By the time the youngest age groups received authorization, the original monovalent vaccines were already being overtaken by variants. Studies confirmed that the vaccines reduced severe COVID-19 and multisystem inflammatory syndrome in children older than five, though data for younger children was more limited.¹⁹

When the original formulations were deauthorized, pediatric versions were pulled along with them. Updated formulations for children followed the same variant-matching logic applied to adult vaccines, though the smaller market and lower perceived urgency among parents meant uptake was generally lower. The practical consequence is that any child receiving a COVID-19 vaccine today receives a formulation updated to match recent circulating strains, not the original 2020 version.

Practical Storage Problems With the First Generation

An underappreciated factor in the lifecycle of the original vaccines was their storage requirements. The first Pfizer-BioNTech vaccine famously needed ultra-cold storage at around minus 70 degrees Celsius, a logistical headache that limited where it could be distributed, especially in lower-resource settings. Moderna’s vaccine was somewhat more forgiving but still required freezer storage. These constraints were a product of the fragility of the lipid nanoparticle formulations used to deliver the mRNA.

Research into lyophilization (freeze-drying) of mRNA-lipid nanoparticle formulations has shown that it is possible to produce shelf-stable versions that maintain their properties for months at refrigerator temperature or even at room temperature without losing effectiveness.²⁰ While these advances did not arrive in time to save the original formulations, they have shaped the development of newer versions and may eventually make mRNA vaccines as easy to store and ship as traditional vaccines. The first-generation cold-chain demands were a real barrier to global distribution, and their removal from the market also meant removing one of the most logistically challenging vaccine products ever deployed.

Patent Fights Between Moderna and Pfizer

The deauthorization of the original formulations did not end the commercial tension between the two companies. Moderna filed patent infringement lawsuits against Pfizer and BioNTech, claiming that Comirnaty infringed on patents Moderna had filed between 2010 and 2016 covering foundational mRNA technology. The dispute centers on the chemical modifications to the mRNA molecule that make it stable enough to use as a vaccine, as well as the lipid nanoparticle delivery systems that carry the mRNA into cells.²¹

These lawsuits are ongoing and cover the technology itself, not just the original products. That means the intellectual property battles will follow both companies into their updated formulations and into entirely new mRNA products for other diseases. The original COVID-19 vaccines may be off the market, but the underlying platform technology is central to both companies’ futures in cancer vaccines, flu vaccines, and treatments for respiratory syncytial virus. Who owns the foundational mRNA innovations will shape competition in the vaccine industry for years, regardless of which specific COVID-19 formulation happens to be authorized at any given moment.

Why This Looks Different From Other Vaccine Withdrawals

When people hear that a vaccine has been “deauthorized,” the instinct is to assume something went wrong. With most recalled pharmaceuticals, the reason is a safety problem discovered after approval. The original Moderna and Pfizer vaccines break that pattern. They were not withdrawn because they harmed people. They were replaced because the target they were designed to hit moved. The closest analogy is the annual reformulation of influenza vaccines, which happens every year without making headlines because the public expects it. COVID-19 vaccine reformulation attracted more attention because it was new, because the initial rollout was politically charged, and because the concept of a vaccine needing an update felt unfamiliar to people accustomed to getting one shot and being done.

The regulatory framework has since shifted toward treating COVID-19 vaccines more like flu vaccines, with annual review cycles where the FDA evaluates which strains are circulating and directs manufacturers to update their formulations accordingly. The original Moderna and Pfizer vaccines did exactly what they were designed to do against the virus they were designed to fight. That virus just stopped being the one making people sick.